With the law changes that came with the Agriculture Improvement Act of 2018, also known as the Farm Bill, the need for FDA clarification and guidance on the regulatory framework has been voiced by advocates, industry representatives, regulators, health professionals, and legalization opponents.

In the remarks made by Dr. Sharpless after the May 31st Public Hearing, he clarified that depending on product type, FDA legal requirements vary. Drugs cannot be sold without FDA approval. However, food, including dietary supplements, is regulated differently. Only new food additives, those not already generally recognized as safe (GRAS), must be FDA approved before being used as a food ingredient.

Dr. Sharpless noted “that several cannabis-derived substances have already come to market through the GRAS pathway,” such as hemp seed ingredients. Nevertheless, CBD and THC are approved drugs and under the Federal Food, Drug & Cosmetic Act adding drugs to human or animal food in interstate commerce is prohibited. He also recognized that there are currently companies selling unapproved CBD products and some, especially those making disease claims have been issued FDA warning letters.

The statement was concluded acknowledging that there are still a lot of questions that need to be answered and the FDA continues to evaluate the use of cannabis and cannabis-derived compounds in FDA-regulated products.

The Tentamus Group, in particular, Tentamus North America, offers various services to assist in ensuring your foods and dietary supplements are compliant:

  • Food and dietary supplement label claim review
  • Food and dietary supplement full label review for FDA compliance
  • Food and dietary supplement ingredient list review
  • Product nutritional analysis and nutrition fact creation and review

The full summary of the Remarks by Dr. Sharpless at the FDA Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds can be found here: https://www.fda.gov/…

Get in touch with our experts. We’re ready to discuss your requirements.

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrochemicals, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 52 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Tentamus Group
An der Industriebahn 5
13088 Berlin, Germany
www.tentamus.com

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com

Ansprechpartner:
Vy Goddard
Regulatory Affairs Specialist, Tentamus North America
E-Mail: vy.goddard@tentamus.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel